These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36592465)

  • 21. Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
    Wexler DJ; Krause-Steinrauf H; Crandall JP; Florez HJ; Hox SH; Kuhn A; Sood A; Underkofler C; Aroda VR;
    Diabetes Care; 2019 Nov; 42(11):2098-2107. PubMed ID: 31391203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The design of the liraglutide clinical trial programme.
    Nauck MA
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():4-12. PubMed ID: 22405264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.
    Suzuki S; Oura T; Takeuchi M; Boye KS
    Health Qual Life Outcomes; 2017 Jun; 15(1):123. PubMed ID: 28606095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study.
    Del Olmo-García MI; Hervás Marín D; Caudet Esteban J; Ballesteros Martin-Portugués A; Cerveró Rubio A; Arnau Vives MA; Catalá Gregori A; Penalba Martínez M; Merino-Torres JF
    J Int Med Res; 2020 Jun; 48(6):300060520926063. PubMed ID: 32567433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
    Aschner P; Chan J; Owens DR; Picard S; Wang E; Dain MP; Pilorget V; Echtay A; Fonseca V;
    Lancet; 2012 Jun; 379(9833):2262-9. PubMed ID: 22683131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Nieuwdorp M; Groen AK; Cahen DL; van Raalte DH
    Diabetes Obes Metab; 2016 Dec; 18(12):1217-1225. PubMed ID: 27451030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial.
    McInnes N; Hall S; Hramiak I; Sigal RJ; Goldenberg R; Gupta N; Rabasa-Lhoret R; Braga M; Woo V; Sultan F; Otto R; Smith A; Sherifali D; Liu YY; Gerstein HC;
    Diabetes Care; 2022 Jan; 45(1):178-185. PubMed ID: 34728531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
    Soliman AR; Fathy A; Khashab S; Shaheen N; Soliman MA
    Exp Clin Transplant; 2013 Dec; 11(6):494-8. PubMed ID: 24344941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of insulin glargine versus sitagliptin in insulin-naïve patients with type 2 diabetes mellitus.
    Brown ST; Grima DG; Sauriol L
    Clin Ther; 2014 Nov; 36(11):1576-87. PubMed ID: 25151573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
    Davies MJ; Chubb BD; Smith IC; Valentine WJ
    Diabet Med; 2012 Mar; 29(3):313-20. PubMed ID: 21883438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of metformin and sitagliptin-based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study.
    Liu X; Wang L; Xing Y; Engel SS; Zeng L; Yao B; Xu W; Chen G; Zhang Y; Zhang R; Liu S; Weng J; Ji Q
    J Diabetes Investig; 2020 Nov; 11(6):1532-1541. PubMed ID: 32304283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pieters-van den Bos IC; Vendrik KE; Hoekstra T; Bruno MJ; Diamant M; van Raalte DH; Cahen DL
    Diabetes Care; 2017 Mar; 40(3):301-308. PubMed ID: 27998910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes.
    Park CY; Kang JG; Chon S; Noh J; Oh SJ; Lee CB; Park SW
    PLoS One; 2014; 9(3):e87799. PubMed ID: 24614911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
    D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
    Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
    Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
    Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
    Kim HS; Shin JA; Lee SH; Kim ES; Cho JH; Son HY; Yoon KH
    Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
    Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
    J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
    Dempsey M; Mocarski M; Langer J; Hunt B
    Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.
    Moses RG; Round E; Shentu Y; Golm GT; O'neill EA; Gantz I; Engel SS; Kaufman KD; Goldstein BJ
    J Diabetes; 2016 Sep; 8(5):701-11. PubMed ID: 26625270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.